Epitope distance to the target cell membrane and antigen size determine the potency of T cell-mediated lysis by BiTE antibodies specific for a large melanoma surface antigen
Bluemel, C. et. al. Cancer Immunol Immunother. Mar 23, epub ahead of print (2010)

Validation of Cynomolgus monkeys as relevant species for safety assessment of a novel human BiTE antibody platform for cancer therapy
Rattel, B. et. al. Annual Meeting of AACR Abstract No. 2435 (2010)

Evidence of a therapeutic window with a T cell-engaging BiTE antibody based on monoclonal antibody cetuximab (Erbitux)
Lutterbuese, R. et. al. Annual Meeting of AACR Abstract No. 2429 (2010)

Novel primate-crossreactive BiTE antibodies that eliminate cancer cells expressing cMet, IGFR-1, FAP-alpha, PSCA, endosialin, CAIX or Her2/neu
Raum, T. et. al. Annual Meeting of AACR Abstract No. 2434 (2010)

Eradication of established pancreatic tumors in mice by engagement of extra-tumoral human T cells with BiTE antibody MT110
Friedrich, M. et. al. Annual Meeting of AACR Abstract No. 2433 (2010)

The CEA/CD3-bispecific antibody MEDI-565 (MT111) binds a nonlinear epitope present in the full-length but not a short splice variant of CEA
Peng, L. et. al. Annual Meeting of AACR Abstract No. 2584 (2010)

Impact of binding epitope and antigen size on the cytotoxic activity of MCSP-specific BiTE antibodies for treatment of melanoma adenocarcinomas
Bluemel, C. et. al. Annual Meeting of AACR Abstract No. 5340 (2010)

In vitro and in vivo pharmacology of MEDI-565 (MT111), a novel CEA/CD3-bispecific single-chain BiTE antibody for the treatment of gastrointestinal adenocarcinomas
Fuhrmann, S. et. al. Annual Meeting of AACR Abstract No. 5625 (2010)

MCSP/CD3 bispecific single-chain antibody construct engages CD4+ and CD8+ T cells for lysis of MCSP-expressing human uveal melanoma cells
Jacobus Bosch, J. et. al. Annual Meeting of AACR Abstract No. 5621 (2010)

Single-chain bispecific BiTE antibody specific for CD3 and melanoma-associated chondroitin sulfate proteoglycan: In vitro and in vivo anti-melanoma activity
Schoellhammer, H. et. al. Annual Meeting of AACR Abstract No. 5626 (2010)

Report of a phase II trial of single-agent BiTE® antibody blinatumomab in patients with minimal residual disease (MRD) positive B-precursor acute lymphoblastic leukemia (ALL)
Topp, M. et. al. Blood (ASH Annual Meeting Abstracts) 114: 840 (2009)

Confirmation of safety, efficacy and response duration in Non-Hodgkin Lymphoma patients treated with 60 μg/m²/d of BiTE® antibody blinatumomab
Nagorsen, D. et. al. Blood (ASH Annual Meeting Abstracts) 114: 2723 (2009)

Identification of a predictive factor for reversible neurological adverse events in a subset of Non-Hodgkin Lymphoma patients treated with CD19-specific BiTE ® antibody blinatumomab
Zugmaier, G. et. al. Blood (ASH Annual Meeting Abstracts) 114: 4793 (2009)

Transient laboratory findings upon first dosing with T-Cell engaging BiTE® antibody blinatumomab in Non-Hodgkin Lymphoma patients
Nagorsen, D. et. al. Blood (ASH Annual Meeting Abstracts) 114: 4798 (2009)

High response rates in cancer patients by a BiTE antibody
Zugmaier, G. and Baeuerle, P.A. Drug Discovery & Development, www.dddmag.com, September 16 (2009)

Safety and pharmacology of the EpCAM/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric or lung cancer
Fiedler, W. et al. ECCO/ESMO Meeting, Berlin, Abstract No. 1254 (2009)

Pharmacodynamic analyses of peripheral blood from relapsed B-NHL patients treated with anti-CD19/-CD3 bispecific BiTE antibody blinatumomab
Klinger, M. et. al. 14th Congress of European Hematology Association, Berlin, abstract no. 482 (2009)

Blinatumomab (anti-CD19 BiTE) for targeted therapy of minimal residual disease (MRD) in patients with B-precursor acute lymphoblastic leukemia (ALL). Update of an ongoing GMALL phase II study
Topp, M.S. et. al. 14th Congress of European Hematology Association, Berlin, abstract no. 430 (2009)

Bispecific T-cell engaging antibodies for cancer therapy
Baeuerle, P.A., Reinhardt, C. Cancer Res. 69: 4941-4944 (2009)

Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab
Nagorsen, D. et. al. Leukemia Lymphoma 50: 1-6 (2009)

Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release
Amann, M. et al.  J Immunother 32: 452-464 (2009)

Potent control of tumor growth by CEA/CD3-bispecific single-chain antibody constructs that are not competitively inhibited by Soluble CEA
Lutterbuese, R. et. al. J Immunother 32: 341-352 (2009)

Highly efficient lysis of KRAS- and BRAF-mutated human colon cancer cells by T cell-engaging BiTE antibodies derived from anti-EGFR antibodies cetuximab and panitumumab
Lutterbuese, R. et al. Annual Meeting of AACR Abstract No. 3251 (2009)

Eradication of colon cancer stem cells by EpCAM/CD3-bispecific BiTE antibody MT110
Muenz, M. et al. Annual Meeting of AACR Abstract No. 3250 (2009)

Effector memory T cells make a major contribution to redirected target cell lysis by T cell-engaging BiTE antibody MT110
Kischel, R. et al. Annual Meeting of AACR Abstract No. 3252 (2009)

In vitro pharmacological comparison of a carcinoembryonic antigen (CEA; CEACAM5; CD66e)/CD3 bispecific cynomolgus-reactive BiTE antibody (CyS111) biosimilar with the clinical candidate MEDI-565 (MT111)
Oberst, M. et al. Annual Meeting of AACR Abstract No. 3247 (2009)

Anti-tumor activity of a T cell-engaging MCSP-specific BiTE antibody at very low effector to target ratios: A new approach to treat metastatic melanoma
Torisu-Itakura, H. et al. Annual Meeting of AACR Abstract No. 3248 (2009)

Effective in vitro lysis of human melanoma cell lines by T lymphocytes redirected with a MCSP/CD3-bispecific single-chain antibody construct is independent of the expression of tumor-associated antigens gp100, MART-1, tyrosinase and NY-ESO1
Aigner, M. et al. Annual Meeting of AACR Abstract No. 4152 (2009)

BiTE: Teaching antibodies to engage T-cells for cancer therapy
Baeuerle, P.A. et. al. Curr Opin Mol Ther 11: 22-30 (2009)

Mode of cytotoxic action of T cell-engaging BiTE antibody MT110
Haas, C. et. al. Immunobiol 214: 441-453 (2009)

Combination of rituximab with blinatumomab (MT103/MEDI-538),
a T cell-engaging CD19-/CD3-bispecific antibody,
for highly efficient lysis of human B lymphoma cells
D'Argouges,  S. et. al. Leuk Res 33: 465-473 (2009)

Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans
Amann, M. et. al. Cancer Immunol Immunother 58: 95-109 (2009)

Can antibodies help cure cancer ?
Baeuerle, P.A. Drug Discovery & Development, www.dddmag.com, May 1 (2009)

Sustained response duration seen after treatment with single agent blinatumomab (MT103/MEDI-538) in the ongoing phase I study MT103- 104 in patients with relapsed NHL
Bargou, R. et. al. Blood (ASH Annual Meeting Abstract) 112: 267 (2008)

Treatment with Anti-CD19 BiTE antibody blinatumomab (MT103 / MEDI-538) is able to eliminate minimal residual disease (MRD) in patients with B-precursor acute lymphoblastic leukemia (ALL): First results of an ongoing phase II study
Topp, M. et. al. Blood (ASH Annual Meeting Abstract) 112: 1926 (2008)

Lysis of cancer cells by autologous T cells in breast cancer pleural effusates treated with anti-EpCAM BiTE antibody MT110
Witthauer, J. et. al. Breast Cancer Res Treat 117: 471-481 (2009)

Tumor regression in cancer patients by very low doses of a
T cell–engaging antibody
Bargou, R. et al. Science 321: 974-977 (2008)
Full article at Science Magazine

Anti-CD19 BiTE antibody MT103 (MEDI-538) study update
confirms high response rate at high dose level including durable
objective responses in patients with relapsed Non-Hodgkin
Lymphoma (NHL). Update from ongoing phase I study MT103-104
Bargou, R. et. al. 10th International Conference on Malignant Lymphoma, Lugano 2008

Serum bioavailability, pharmacodynamic activity, and anti-tumor efficacy of the CD19/CD3 specific BiTE antibody MEDI-538 (MT103/blinatumomab) delivered subcutaneously in animal models
Mulgrew, K. et. al. Proc Am Assoc Cancer Res 99: Abs 2131 (2008)

Feasibility of subcutaneous delivery supports a new route of administration for treating cancer patients with EpCAM-specific BiTE antibody MT110
Schlereth, B. et. al. Proc Am Assoc Cancer Res 99: Abs 2131 (2008)

Characterization in primates of MCSP- and CD33-specific human BiTE antibodies for treatment of Melanoma and AML

Kischel, R. et. al. Proc Am Assoc Cancer Res 99: Abs 2404 (2008)

Long-term treatment of mice with an EpCAM specific BiTE antibody reveals a therapeutic window and sustained activity of T-Cells

Amann, M. et. al. Proc Am Assoc Cancer Res 99: Abs 2130 (2008)

Conversion of cetuximab, panitumumab, trastuzumab and omalizumab into T-cell-engaging BiTE antibodies creates
novel drug candidates of high potency

Lutterbuese, R. et. al. Proc Am Assoc Cancer Res 99: Abs 2402 (2008)

BiTE: a new class of antibodies that recruit T-cells

Baeuerle, P.A. et al. Drugs Future 33: 137-147 (2008)

Therapeutic window of MuS110, a single-chain antibody construct bispecific for murine EpCAM and murine CD3

Amann, M. et al. Cancer Res 68: 143-151 (2007)

Anti-CD19 BiTE antibody MT103 (MEDI-538) induces dose-dependent objective complete and partial responses in relapsed non-Hodgkin lymphoma (NHL) patients. Update from ongoing phase I study MT103-104
Bargou, R. et al. Blood (ASH Annual Meeting Abstract) 110: 2557 (2007)

Therapeutic window of a single-chain antibody construct bispecific for EpCAM and CD3
Baeuerle, P.A. et al. Annual Meeting of AACR-NCI-EORTC Abstract No. C270 (2007)

Mode of action of MT110, a novel bispecific single-chain antibody of the BiTE® class for treatment of adeno and squamous cell carcinoma expressing EpCAM (CD326)
Haas, C. et al. Annual Meeting of AACR-NCI-EORTC Abstract No. C267 (2007)

Highly efficient elimination of melanoma cells expressing melanoma-associated chondroitin sulfate proteoglycan (MCSP)
by MCSP/CD3-bispecific single-chain antibody constructs
Kischel, R. et al. Proc Am Assoc Cancer Res Abs A61 (2007)

Selective targeting and potent control of tumor growth by an EphA2/CD3-bispecific single-chain antibody construct     
Hammond, S.A. et el. Cancer Res 67: 3927-3935 (2007)

Strictly target cell-dependent activation of T cells by bispecific single-chain antibody construicts of the BiTE class    
Brischwein, K. et al. J Immunother 30: 798-807 (2007)

The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19-/CD3-bispecific single-chain antibody construct     
Brandl, C. et al. Cancer Immunol Immunother 56: 1551-1563 (2007)

CD19/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis     
Molhoj, M. et al. Mol Immunol 44: 1945-1953 (2007)

T cell responses during long-term continuous infusion of MT103 (MED-538; Anti-CD19 BiTE) in patients with relapsed B-NHL: data from dose-escalation study MT103-104
Klinger, M. et al. Blood 108: 2725 (2006)

The bi-specific T-cell enhancer (BiTE) MT103 (MEDI-538) induces clinical responses in heavily pre-treated NHL patients: update from the ongoing phase I study MT103-104     
Bargou, R. et al. Blood 108: 693 (2006)

MT103 (anti-CD19 x anti-CD3-BiTE) induces B cell depletion, clearance of bone marrow infiltration and clinical responses in heavily pre-treated NHL patients: first data from dose-escalation study MT103-104
Bargou, R. et al. Haematologia 91 (S1): 71 (2006)

Differential targeting and potent killing of tumors using a single-chain EphA2/CD3-bispecific antibody construct     
Roff, S. et al. Poster at Annual Meeting of the American Association of Cancer Research (2006)

Potent inhibition of local and disseminated tumor growth in immunocompetent mice by a bispecific single-chain antibody construct specific for murine CD3
Schlereth, B. et al. Cancer Immunol Immunother 55: 785-796 (2006)

MT110: A novel bispecific single-chain antibody construct with high efficacy in eradicating solid tumors
Brischwein, K. et al. Mol Immunol 43:1129-1143 (2006)

T cell activation and B cell depletion in chimpanzees treated with a anti-CD19/anti-CD3 single-chain bispecific antibody construct
Schlereth, B. et al. Cancer Immunol Immunother 55: 503-14 (2006)

Induction of regular cytolytic T cell synapses by bispecific single-chain antibody constructs
Offner, S. et al. Mol Immunol 43: 763-71 (2006)

Serial killing of tumor cells by cytotoxic T cells activated through a bispecific single-chain antibody construct
Hoffmann, P. et al. Int J Cancer 115: 98-104 (2005)

Eradication of tumors from a human colon cancer cell line and primary ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct
Schlereth, B. et al. Cancer Res 56: 2882-2889 (2005)

A revival of bispecific antibodies
Kufer, P. et al. Trends Biotechnol 22: 238-244 (2004)

A bispecific single-chain antibody fusion protein for the targeted depletion of autoreactive B cells via unstimulated human T lymphocytes
Zocher, M. et al. Mol Immunol 41: 511-518 (2004)

Efficient tumor cell lysis by autologous, tumor-resident T lymphocytes in primary ovarian cancer samples by an Ep-CAM-/CD3-bispecific antibody
Wimberger, P. et al. Int J Cancer 105: 241-248 (2003)

Bispecific antibodies for polyclonal T cell engagement
Baeuerle, P.A. et al. Curr Opin Mol Ther 5: 413-419 (2003)

T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct
Dreier, T. et al. J Immunol 170: 4397-4402 (2003)

Extremely potent, rapid and costimulation-independent cytotoxic T cell response against B lymphoma cells catalyzed by a single-chain bispecific antibody
Dreier, T. et al. Int J Cancer 100: 690-697 (2002)